Retinitis pigmentosa stem cell therapy trial tops 2019 retina news
Click Here to Manage Email Alerts
The top retina-related stories on Healio.com/OSN in 2019 included trial results, meeting coverage and FDA approvals.
Here are the top five most-read retina articles of the year:
Phase 2a study shows improved vision with stem cell therapy for retinitis pigmentosa
Human retinal progenitor cell therapy from ReNeuron Group is showing positive preliminary results in the company’s ongoing phase 1/2a clinical trial involving patients with retinitis pigmentosa. Read more.
Protocol V trial results favor observation strategy for DME with good vision
The DRCR.net Protocol V clinical trial concludes that patients with center-involved diabetic macular edema and good vision can confidently be managed by observation, scheduling anti-VEGF injections only if vision deteriorates. Read more.
Surgeons perform first gene therapy procedure aimed at stopping AMD-related blindness
The procedure involved detaching the retina and injecting a virus-containing solution underneath. The modified DNA sequence contained in the virus infects the retinal pigment epithelium cells and corrects the genetic defect that causes AMD. Read more.
Two phase 3 trials to investigate faricimab for wet AMD
Roche and Genentech are initiating two phase 3 global trials to investigate the bispecific molecule faricimab for the treatment of wet age-related macular degeneration. Read more.
FDA approves Novartis’ Beovu for wet AMD
Brolucizumab-dbll, called Beovu, demonstrated noninferiority vs. aflibercept in the phase 3 HAWK and HARRIER clinical trials and is the first FDA-approved anti-VEGF to maintain wet AMD patients on a 3-month dosing interval after a 3-month loading phase. Read more.